secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0000886744-25-000068
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron Q3 2025 RYTELO revenue $47.2M; net loss narrows to $18.4M; FY25 opex guidance lowered
--------------------------------------------------------------------------------

- RYTELO net product revenue $47.2M in Q3 2025 (vs $28.2M in Q3 2024); demand down 3% QoQ.
- Net loss $18.4M ($0.03/share) compared to $26.4M ($0.04/share) in Q3 2024.
- Completed enrollment of 320 patients in Phase 3 IMpactMF trial for imetelstat in myelofibrosis.
- FY 2025 operating expense guidance reduced to $250M-260M from prior $270M-285M.
- Appointed Ahmed ElNawawi as EVP, Chief Commercial Officer; three other executives added.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/0000886744-25-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/gern-20251105.htm
  HTML page:      https://secwatch.observer/filing/0000886744-25-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer